Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (3.910.778 €): VERSTEHEN DER CLOSTRIDIUM SPORE, EIN PREREQUISTE FÜR DISEASE INTERVENTIONS UND EXPLOITATION Hor01.01.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
VERSTEHEN DER CLOSTRIDIUM SPORE, EIN PREREQUISTE FÜR DISEASE INTERVENTIONS UND EXPLOITATION
Bacterial endospores are the most resistant life-forms on earth and the most important single feature of the genus Clostridium. Thus, whilst the pathogenesis of its notorious pathogens (C. botulinum, C. perfringens and C. difficile) is ascribed to the devastating toxins produced (neurotoxins, endotoxins and cytotoxins), it is their capacity to produce spores that lies at the heart of the diseases they cause. This is because spores play the pivotal role in the spread of infection (eg, C. difficile) and in foodstuff contamination and food poisoning (eg, C. botulinum and C. perfringens). The processes of spore formation (sporulation) and germination (return of the dormant spore to toxin-producing, vegetative cells), therefore, represent key intervention points. On the other hand, the majority of clostridia are entirely benign and can sustainably produce all manner of useful chemicals and fuels. Crucially, the regulation of chemical production is intimately linked to that of sporulation. Spores of benign species may also be used as a delivery system for treating cancer. Yet, despite the spore’s importance, little is known of the developmental processes of sporulation and germination. This is because research and training efforts on Clostridium spores are fragmented and there is no coherence between researchers working on pathogenic and industrially important species. CLOSPORE will address this deficiency by pooling the resources of Europe’s leading universities, research organisations and companies, to create an intersectorial Research and Training Programme that is multi-facetted, interdisciplinary and focused on clostridial spores. Accordingly, CLOSPORE will produce the innovative, applied research leaders of the future, able to tackle the big societal challenges facing Europe and the world.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Astellas Pharma Europe Ltd. | ? |
| Biocleave Ltd. | 273.288 € |
| HELSINGIN YLIOPISTO | 538.291 € |
| Institut Pasteur | 525.751 € |
| 510.749 € | |
| Purac Biochem B.V. | 510.749 € |
| Stichting Wageningen Research | 255.374 € |
| The University of Nottingham | 819.864 € |
| 476.713 € |
Quelle: https://cordis.europa.eu/project/id/642068
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Astellas Pharma Europe Ltd., Addlestone, Großbritannien.
Die Visualisierungen zu "Astellas Pharma Europe Ltd. - EU-Förderung (3.910.778 €): VERSTEHEN DER CLOSTRIDIUM SPORE, EIN PREREQUISTE FÜR DISEASE INTERVENTIONS UND EXPLOITATION"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
